Vaidya Sane Ayurved Laboratories Limited (NSE:MADHAVBAUG)
India · Delayed Price · Currency is INR 147.00
+6.75 (4.81%)
Nov 12, 2026, 3:29 PM IST
NSE:MADHAVBAUG Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,156 | 1,069 | 899.23 | 993.31 | 991.69 | 747.11 |
Other Revenue | 9.74 | - | 17.82 | - | - | - |
| 1,166 | 1,069 | 917.04 | 993.31 | 991.69 | 747.11 | |
Revenue Growth | 19.02% | 16.58% | -7.68% | 0.16% | 32.74% | 42.92% |
Cost of Revenue | 230.33 | 213.44 | 208.82 | 279.61 | 298.93 | 241.25 |
Gross Profit | 935.9 | 855.63 | 708.22 | 713.7 | 692.76 | 505.86 |
Selling, General & Admin | 533.89 | 502.91 | 379.05 | 456.23 | 423.06 | 267.72 |
Other Operating Expenses | 310.77 | 198.49 | 168.12 | 212.44 | 191.13 | 167.11 |
Operating Expenses | 907.41 | 762.73 | 588.72 | 700.09 | 640.17 | 457.68 |
Operating Income | 28.49 | 92.9 | 119.5 | 13.62 | 52.59 | 48.18 |
Interest Expense | -3.63 | -1.54 | -1.19 | -2.48 | -1.88 | -2.02 |
Interest & Investment Income | 19.64 | 19.64 | - | 9.04 | 8.73 | 1.47 |
Earnings From Equity Investments | -0.05 | -0.02 | -0.17 | -0.11 | - | - |
Other Non Operating Income (Expenses) | -2.89 | -2.89 | -7.3 | 4.98 | 4.89 | -0 |
EBT Excluding Unusual Items | 41.57 | 108.1 | 110.85 | 25.04 | 64.33 | 47.64 |
Gain (Loss) on Sale of Investments | - | - | - | 3.42 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | 0.07 | - | - |
Other Unusual Items | -0.06 | -0.06 | -12.03 | - | - | -0.15 |
Pretax Income | 41.51 | 108.04 | 98.82 | 28.54 | 64.33 | 47.49 |
Income Tax Expense | 2.21 | 18.16 | 27.45 | 8.74 | 16 | 12.8 |
Earnings From Continuing Operations | 39.3 | 89.88 | 71.37 | 19.79 | 48.33 | 34.69 |
Minority Interest in Earnings | 0 | -0.01 | -0.01 | 0.01 | -0.01 | - |
Net Income | 39.3 | 89.87 | 71.36 | 19.8 | 48.33 | 34.69 |
Net Income to Common | 39.3 | 89.87 | 71.36 | 19.8 | 48.33 | 34.69 |
Net Income Growth | -52.13% | 25.93% | 260.34% | -59.02% | 39.32% | 784.92% |
Shares Outstanding (Basic) | 10 | 11 | 11 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | 10 | 11 | 12 | 12 | 11 | 11 |
Shares Change | -1.27% | -9.38% | 0.00% | 17.37% | - | 50.73% |
EPS (Basic) | 3.76 | 8.51 | 6.79 | 1.88 | 4.60 | 3.30 |
EPS (Diluted) | 3.76 | 8.04 | 5.78 | 1.57 | 4.60 | 3.30 |
EPS Growth | -51.51% | 39.10% | 268.15% | -65.85% | 39.32% | 487.10% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -129.25 | -24.67 | 172.56 | -124.09 | -69.15 | -162.95 |
Free Cash Flow Per Share | -12.38 | -2.21 | 13.98 | -10.06 | -6.58 | -15.50 |
Dividend Per Share | - | - | - | - | 0.500 | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 80.25% | 80.03% | 77.23% | 71.85% | 69.86% | 67.71% |
Operating Margin | 2.44% | 8.69% | 13.03% | 1.37% | 5.30% | 6.45% |
Profit Margin | 3.37% | 8.41% | 7.78% | 1.99% | 4.87% | 4.64% |
Free Cash Flow Margin | -11.08% | -2.31% | 18.82% | -12.49% | -6.97% | -21.81% |
EBITDA | 89.17 | 149.27 | 159.43 | 45.03 | 78.57 | 68.68 |
EBITDA Margin | 7.65% | 13.96% | 17.39% | 4.53% | 7.92% | 9.19% |
D&A For EBITDA | 60.68 | 56.37 | 39.93 | 31.42 | 25.98 | 20.5 |
EBIT | 28.49 | 92.9 | 119.5 | 13.62 | 52.59 | 48.18 |
EBIT Margin | 2.44% | 8.69% | 13.03% | 1.37% | 5.30% | 6.45% |
Effective Tax Rate | 5.33% | 16.81% | 27.78% | 30.64% | 24.87% | 26.95% |
Revenue as Reported | 1,190 | 1,093 | 917.04 | 1,011 | 1,005 | 750.49 |
Advertising Expenses | - | - | - | 137.62 | 159.29 | 85.94 |